menu search

BGNE / Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery. Read More
Posted: Sep 24 2023, 22:33
Author Name: Seeking Alpha
Views: 101835

BGNE News  

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

By Seeking Alpha
September 24, 2023

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a more_horizontal

BeiGene regains rights for cancer drug after Novartis deal termination

By Reuters
September 19, 2023

BeiGene regains rights for cancer drug after Novartis deal termination

BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis. more_horizontal

7 Best Cancer Stocks to Invest in Now

By MarketBeat
July 28, 2023

7 Best Cancer Stocks to Invest in Now

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. more_horizontal

BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?

By Zacks Investment Research
April 10, 2023

BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?

BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. more_horizontal

Why BeiGene Stock Jumped Thursday

By The Motley Fool
April 6, 2023

Why BeiGene Stock Jumped Thursday

BeiGene's shares are up more than 8% this year. The company has more than 60 clinical programs. more_horizontal

BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024

By Forbes
March 22, 2023

Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)

By Zacks Investment Research
February 28, 2023

Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)

BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. more_horizontal

Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 Weeks

By Zacks Investment Research
February 27, 2023

Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 Weeks

BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal


Search within

Pages Search Results: